Stephanie has growth hormone deficiency
  •  

Growth disorders/growth hormone

Our ambition

We created the world’s first liquid, pre-mixed human growth hormone delivered in a dedicated pen system, Norditropin® SimpleXx®.

Novo Nordisk has been a major player in the field of growth hormone therapy for many decades, and we have world-class expertise in the physiology and pathophysiology of growth and regeneration. We hold a leading position in the global growth hormone market, aiming for a leadership position – and we keep exploring new modalities to treat human growth hormone disorders.

Our partnering focus

We seek technologies and compounds:

  • With long-acting potential
  • Suitable for oral administration

Read more about Biopharmaceuticals Research Unit

Contact us

For further information, please contact Jørn Müller 


  •  

Download partnering for innovation brochure

  •  
  •  

Where to meet us

We are attending events all over the world to meet with new potential partners.

Event calendar

  •